Skip to main content

Analysts’ Top Healthcare Picks: United Therapeutics (UTHR), TG Therapeutics (TGTX)

Tipranks - Tipranks - Fri Feb 27, 12:04PM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on United Therapeutics (UTHR – Research Report) and TG Therapeutics (TGTX – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

United Therapeutics (UTHR)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on United Therapeutics, with a price target of $600.00. The company’s shares closed last Thursday at $499.34.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 29.3% and a 57.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and KalVista Pharmaceuticals. ;'>

United Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $578.78, representing a 9.2% upside. In a report issued on February 17, UBS also maintained a Buy rating on the stock with a $645.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

TG Therapeutics (TGTX)

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on TG Therapeutics, with a price target of $60.00. The company’s shares closed last Thursday at $30.22.

According to TipRanks.com, Bodnar is a 4-star analyst with an average return of 12.9% and a 35.2% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., Acrivon Therapeutics, Inc., and Olema Pharmaceuticals. ;'>

Currently, the analyst consensus on TG Therapeutics is a Moderate Buy with an average price target of $42.00, representing a 47.9% upside. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $50.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).